GERN — Geron Corporation stock price, charts and financials

QT51Geron Corporation

Geron Corporation (NASDAQ: GERN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1.50
+0.02+1.35%
OverviewShort InterestFilings
GERNQT51Geron Corporation·NASDAQ
1.50+1.35%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.24%$15.49MESO+4.92%$16.73ZBIO-0.80%$32.17GHRS-1.85%$29.71TSHA-0.67%$6.52STOK-1.01%$32.38ABCL+32.25%$9.16VRDN-1.42%$23.26
Snapshot
Index-P/E-EPS (ttm)-0.10Insider Own5.39%Shs Outstand641.52MPerf Week14.73%
Market Cap949.45MForward P/E20.00EPS next Y0.07Insider Trans-0.03%Shs Float560.06MPerf Month-5.13%
Enterprise Value1.01BPEG-EPS next Q-Inst Own-Short Float12.48%Perf Quarter1.37%
Income-66.84MP/S4.64EPS this Y57.50%Inst Trans-Short Ratio5.01Perf Half Y1.37%
Sales204.56MP/B4.54EPS next Y274.12%ROA-13.47%Short Interest69.92MPerf YTD12.12%
Book/sh-P/C-EPS next 5Y-ROE-30.31%52W High2.04 -26.37%Perf Year6.47%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-8.32%52W Low1.05 42.31%Perf 3Y-53.89%
Dividend Est.-EV/EBITDA-Sales past 3/5Y468.77% -Gross Margin83.21%Volatility8.76% 6.48%Perf 5Y20.33%
Dividend TTM-EV/Sales4.93EPS Y/Y TTM62.96%Oper. Margin-18.29%ATR (14)0.10Perf 10Y-46.18%
Dividend Ex-Date-Quick Ratio5.16Sales Y/Y TTM154.55%Profit Margin-34.17%RSI (14)54.30Recom2.32
Dividend Gr. 3/5Y-Current Ratio6.92EPS Q/Q-SMA203.86%Beta0.60Target Price5.89
Payout0.00%Debt/Eq0.56Sales Q/Q30.00%SMA5010.60%Rel Volume0.68Prev Close1.48
Employees258LT Debt/Eq1.03EarningsNov 04SMA2005.42%Avg Volume13.03MPrice1.50
IPO DateJul 31, 1996Option/ShortNo / YesEPS/Sales Surpr.38.61% 2.47%Net Debt/EBITDA-1.43Volume8,884,008Change1.35%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-25DowngradeScotiabankSector Outperform → Sector Perform
Feb-27-25DowngradeB. Riley SecuritiesBuy → Neutral
Feb-27-25ReiteratedBarclaysOverweight$4.00
Feb-26-25DowngradeHC Wainwright & Co.Buy → Neutral
Oct-22-24ReiteratedB.Riley FinancialBuy$5.50
Sep-09-24InitiatedLeerinkOutperform
Jun-10-24ReiteratedGoldman SachsBuy$5.00
Jun-10-24ReiteratedStifel NicolausHold
Apr-30-24ReiteratedRobert W. Baird$4.50
Apr-30-24DowngradeBairdOutperform → Neutral
Latest News
Aug-05-26
Aug-05-2612:53PM
Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than ExpectedChartMill
11:00AM
Geron Corporation (GERN) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:01AM
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimateszacks.com
09:04AM
Geron Q2 Earnings Call Highlightsmarketbeat.com
07:00AM
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlightsglobenewswire.com
Aug-04-26
Aug-04-2603:44AM
Geron (GERN) Expected to Announce Quarterly Earnings on Wednesdaydefenseworld.net
Jul-22-26
Jul-22-2604:01PM
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
07:00AM
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com
Jul-15-26
Jul-15-2609:00AM
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairmanglobenewswire.com
Jul-14-26
Jul-14-2604:26PM
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-13-26
Jul-13-2608:00AM
Geron Announces Appointment of Chinmaya Rath as Chief Business Officerglobenewswire.com
Jul-01-26
Jul-01-2610:11AM
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Upseekingalpha.com
Company

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue20418477——————
Cost of Goods Sold Incl. D&A3451——————
Gross Profit17017976——————
Selling, General and Administrative Excl. Other155159146——————
Research and Development7474104——————
Other Operating Expense-220-1——————
Operating Income-37-54-174——————
Interest Expense303319——————
Unusual Expense
—————————
Non-Operating Income (Expense)-2118——————
Net Income Before Taxes-70-86-175——————
Income Taxes
000——————
Consolidated Net Income-70-86-175——————
Net Income From Continuing Operations-70-86-175——————
Net Income-70-86-175——————
EPS (Recurring)-0.10-0.13-0.27——————
EPS (Basic, Before Extraordinaries)-0.10-0.13-0.27——————
EPS (Diluted)-0.10-0.13-0.27——————
EBITDA-42-52-155——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio4.934.7929.70——————
Gross Margin83.3397.2898.70——————
Operating Margin-18.14-29.35-225.97——————
Net Margin-34.31-46.74-227.27——————
Shares Outstanding671667646——————
Market Capitalization1,0078802,287——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$2.08$1.80$1.51$1.22$0.94● Close Price0.00K4.78K9.56K14.34K19.12KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Option Exercise0.0027,500027,500Feb 19
ROBERTSON MICHELLEEVP, CHIEF FINANCIAL OFFICERFeb 18 '26Sale1.949,85519,11917,645Feb 19
LAWLIS V BRYANDirectorMay 09 '25Buy1.1813,30015,66713,300May 13
Samuels Scott AlanEVP, Chief Legal OfficerFeb 27 '25Buy1.6115,00024,15026,682Mar 03
SCARLETT JOHN AChairman, President and CEOFeb 27 '25Buy1.7612,50022,06312,500Mar 03
Ziegler JamesEVP, Chief Commercial OfficerFeb 27 '25Buy1.60100,000160,000100,000Mar 03
GRETHLEIN ANDREW JEVP, Chief Operating OfficerJul 08 '24Option Exercise1.721,127,1521,938,702674,348Jul 10
GRETHLEIN ANDREW JEVP, Chief Operating OfficerJul 08 '24Sale4.56674,3483,073,0040Jul 10
Feller FayeEVP, Chief Medical OfficerJun 10 '24Option Exercise1.19287,900341,693155,400Jun 12
Feller FayeEVP, Chief Medical OfficerJun 10 '24Sale4.63287,9001,334,1290Jun 12
Kapur AnilEVP, Corp Strategy & CCOJun 10 '24Option Exercise1.06421,875447,188421,875Jun 12
Kapur AnilEVP, Corp Strategy & CCOJun 10 '24Sale4.64421,8751,959,6090Jun 12
SCARLETT JOHN AChairman, President and CEOJun 04 '24Sale4.00600,0002,400,000600,000Jun 05
SCARLETT JOHN AChairman, President and CEOJun 04 '24Option Exercise2.54600,0001,524,000600,000Jun 05
LAWLIS V BRYANDirectorMay 15 '24Option Exercise1.9435,00067,90035,000May 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.